Treace Medical Concepts, Inc. TMCI
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.38M | 47.20M | 62.52M | 50.21M | 47.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.38M | 47.20M | 62.52M | 50.21M | 47.39M |
| Cost of Revenue | 9.77M | 9.79M | 12.12M | 10.51M | 9.64M |
| Gross Profit | 35.61M | 37.41M | 50.40M | 39.71M | 37.75M |
| SG&A Expenses | 46.19M | 49.95M | 51.78M | 49.70M | 49.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.33M | 64.37M | 68.44M | 64.89M | 64.36M |
| Operating Income | -14.96M | -17.17M | -5.92M | -14.68M | -16.97M |
| Income Before Tax | -15.87M | -17.96M | -9.39M | -16.29M | -17.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.87M | -17.96M | -9.39M | -16.29M | -17.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.87M | -17.96M | -9.39M | -16.29M | -17.40M |
| EBIT | -14.96M | -17.17M | -5.92M | -14.68M | -16.97M |
| EBITDA | -13.07M | -16.27M | -4.11M | -11.90M | -14.40M |
| EPS Basic | -0.24 | -0.28 | -0.15 | -0.26 | -0.28 |
| Normalized Basic EPS | -0.15 | -0.17 | -0.07 | -0.15 | -0.17 |
| EPS Diluted | -0.24 | -0.28 | -0.15 | -0.26 | -0.28 |
| Normalized Diluted EPS | -0.15 | -0.17 | -0.07 | -0.15 | -0.17 |
| Average Basic Shares Outstanding | 65.05M | 64.59M | 63.86M | 63.52M | 63.01M |
| Average Diluted Shares Outstanding | 65.05M | 64.59M | 63.86M | 63.52M | 63.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |